Single Psilocybin Dose Relieves OCD for Months — What the Yale Study Found

Can psilocybin treat OCD? A groundbreaking Yale University study says yes — and the results are remarkable. In this first-ever randomized, placebo-controlled trial, just one dose of psilocybin — the psychoactive compound in magic mushrooms — reduced obsessive-compulsive disorder symptoms within 48 hours. Even more striking, the benefits lasted for months. For the millions of people living with treatment-resistant OCD, this psilocybin OCD research opens an entirely new door.

What Is OCD — and Why Do Current Treatments Fail?

Obsessive-compulsive disorder (OCD) is a mental health condition that causes unwanted, intrusive thoughts (obsessions) and repetitive behaviours (compulsions). For example, a person might feel an overwhelming fear of contamination and then wash their hands dozens of times a day. In fact, OCD affects roughly 2–3% of the global population — that is about 200 million people worldwide.

However, the real problem is treatment. Standard care for OCD usually involves a type of therapy called Exposure and Response Prevention (ERP) and medications called SSRIs (selective serotonin reuptake inhibitors). Unfortunately, these treatments do not work for everyone. According to clinical data, approximately 40–60% of patients do not respond well to first-line medications. As a result, many people with OCD live with significant symptoms for years — even decades — without relief. This is why researchers are now exploring psilocybin as a potential OCD treatment.

How Psilocybin Works in the OCD Brain

Psilocybin is the naturally occurring psychoactive compound found in over 200 species of mushrooms, commonly known as magic mushrooms. After you ingest psilocybin, your body quickly converts it into psilocin — the molecule that actually produces effects in the brain.

Psilocin works mainly by activating a specific serotonin receptor called 5-HT2A. This receptor is found in high concentrations in the prefrontal cortex — the part of the brain responsible for complex thinking, decision-making, and self-awareness. Activating 5-HT2A receptors triggers a cascade of changes: it increases excitatory neurotransmission, promotes the growth of new connections between brain cells (a process known as neuroplasticity), and temporarily disrupts rigid patterns of brain activity.

In conditions like OCD, the brain often gets "stuck" in repetitive loops. Therefore, researchers believe that psilocybin may help by breaking these OCD loops and allowing the brain to form healthier patterns. This is fundamentally different from SSRIs, which simply increase overall serotonin levels without resetting brain connectivity.

The Yale Psilocybin OCD Study: How It Was Done

The landmark trial was led by researchers Benjamin Kelmendi and Christopher Pittenger at the Yale School of Medicine. It is officially registered as NCT03356483 on ClinicalTrials.gov, and the results were published as a preprint on OSF Preprints (DOI: 10.31234/osf.io/atfum).

Here is what the researchers did:

Psilocybin OCD Results: Fast, Strong, and Lasting

The results of this psilocybin OCD trial were striking — both in speed and magnitude.

In simpler terms: psilocybin moved OCD patients from severe to moderate or mild — within just two days. Meanwhile, the placebo group stayed exactly where they started. Moreover, when the niacin participants crossed over and also received psilocybin, they experienced similar improvements, with a 6.14-point A-YBOCS decrease at 48 hours and 35.7% achieving response at one week.

What Experts Say About Psilocybin for OCD

The reaction from the scientific community has been overwhelmingly positive — though cautious. Alex Kwan, a neuroscientist at Cornell University, described the results as follows: "The rapidity and sustainability of the improvement observed following a single psilocybin dose are striking."

David Nutt, a professor of neuropsychopharmacology at Imperial College London who led a related open-label psilocybin OCD trial, added that psilocybin appears "more effective and quicker than other OCD medications." This is significant because Nutt is one of the most cited psychedelic researchers in the world.

Christopher Pittenger, the senior author of the Yale study, was more measured. He emphasised that larger psilocybin OCD trials are needed to confirm these findings, determine the best dosing strategy, and identify which patients benefit the most — and who may be at risk.

Safety of Psilocybin in OCD Treatment

Outside of this serious adverse event, psilocybin was generally well tolerated. The 0.25 mg/kg dose was enough to produce a full psychedelic experience — which Pittenger described as "quite intense, although experiences vary significantly among individuals." However, no other serious adverse events were reported during the trial period.

This safety profile is consistent with other psilocybin research. In most clinical trials, side effects tend to be temporary and include nausea, headache, and psychological discomfort during the session itself. Nevertheless, the case in this trial underlines why medical supervision is essential — especially for patients with a history of suicidal ideation.

Psilocybin OCD Treatment vs. Standard Care

To understand how remarkable these psilocybin OCD results are, it helps to compare them to what is currently available.

Consequently, the speed of psilocybin is especially noteworthy. SSRIs typically take 4 to 12 weeks before patients feel any benefit — and that is if they work at all. By contrast, psilocybin showed measurable OCD symptom reduction within 48 hours after a single dose.

A Second Psilocybin OCD Study Supports the Findings

It is worth noting that a separate UK-based study, published in Comprehensive Psychiatry, also tested psilocybin for OCD — this time with a lower dose (10 mg). In that trial, 19 adult participants received both a 1 mg and a 10 mg dose of psilocybin in a fixed order, four weeks apart.

At one week, the 10 mg dose produced a significant effect on the Y-BOCS compulsion subscale (Cohen's d = 0.74, p = 0.003). In other words, even at a lower dose, psilocybin specifically reduced OCD compulsive behaviours. However, the effect faded over the following three weeks, suggesting that higher or repeated doses may be needed for lasting benefit.

Together, these two psilocybin OCD studies build a growing evidence base that psilocybin has real potential for treating obsessive-compulsive disorder — especially in patients who have not responded to standard care.

What Is Next for Psilocybin and OCD Research?

The Yale team is already running a follow-up psilocybin OCD trial: NCT05370911. This new study tests repeated psilocybin dosing (two sessions instead of one) to see whether multiple doses lead to even greater and longer-lasting improvements in OCD symptoms. It uses an adaptive dosing strategy — 25 mg for the first dose and 25 or 30 mg for the second — and follows participants for up to 12 months.

Meanwhile, research into psilocybin for mental health continues to accelerate globally. Compass Pathways recently reported positive Phase 3 results for psilocybin in treatment-resistant depression. In addition, the U.S. DEA has increased its 2026 production quota for psilocybin by 67% specifically to support growing research demand. These developments suggest that psilocybin-based treatments — including for OCD — may reach mainstream clinical use within the next few years.

Why Psilocybin OCD Research Matters

For the estimated 80 to 120 million people worldwide who suffer from treatment-resistant OCD, these findings represent genuine hope. Current treatments leave many patients stuck — sometimes for decades — with a condition that the WHO ranks among the top causes of disability worldwide. Psilocybin offers something fundamentally different: a single-dose intervention that works fast, lasts months, and appears to reset the brain circuits that keep OCD running.

Of course, more psilocybin OCD research is needed. Larger trials must confirm these findings, and questions remain about optimal dosing, long-term safety, and which patients benefit the most. But as the scientific evidence grows, one thing is clear: magic mushrooms are no longer just a curiosity — they are becoming serious medicine.